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Background
Stevens-Johnson syndrome and toxic epidermal necrolysis
(SJS/TEN) are severe cutaneous adverse reactions that are
associated with high mortality. Mainly due to rareness, but
also due to unpredictable onset and rapid course, thera-
peutic effects are often studied in observational settings.
Since an evidence-based standardized treatment protocol
for SJS/TEN is still lacking, we intended to combine infor-
mation and evidence from any type of study to provide a
comprehensive overview on immunomodulating therapies
and their potential effects in comparison to supportive
care only.
Methods
A systematic literature search regarding publications on
therapy of SJS/TEN was performed for the period from
1990 to 2012. Any type of study meeting predefined
inclusion criteria was included. Data were extracted from
published articles. Study groups were contacted to get
further information. Eventually, all studies were assessed
for final inclusion. To evaluate therapeutic effects we
conducted a meta-analyses based on aggregated as well
as on individual patient data (IPD).
Results
Besides dozens of observational studies only one rando-
mized controlled trial have been found. The quality of
most studies has been assessed as low. 96 studies
including 3451 patients passed our selection process.
The majority of them focussed on SJS/TEN-patients
treated with supportive care, glucocorticosteroids or
intravenous immunoglobulines. Few studies evaluated
other immunomodulating therapies like ciclosporin,
plasmapheresis, cyclophosphamide and thalidomide.
Besides monotherapy with one immunomodulating
agent combined treatment modalities were also
observed. Only 17 studies (18%) assessed therapy effects
and are thus principally eligible for inclusion in our
common meta-analysis. For the IPD analysis, 1209
patients (35%) with complete information are available.
Both analyses are currently ongoing. The results will be
presented.
Conclusion
The comprehensive overview about possible therapies
for SJS/TEN revealed no unexpected treatment options.
Final results of both analyses are awaited for estimating
the efficacy of immunomodulating therapies in compari-
son to supportive care only related to mortality and for
providing hypotheses on most promising treatment.
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